IGMS IGM Biosciences Inc

Price (delayed)

$70.52

Market cap

$2.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.56

Enterprise value

$2.03B

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing ...

Highlights
IGM Biosciences's debt has decreased by 6% YoY and by 5% from the previous quarter
IGM Biosciences's equity has soared by 56% YoY but it has decreased by 9% from the previous quarter
The EPS has dropped by 146% year-on-year and by 18% since the previous quarter
The company's net income has shrunk by 88% YoY and by 21% QoQ

Key stats

What are the main financial stats of IGMS
Market
Shares outstanding
32.06M
Market cap
$2.26B
Enterprise value
$2.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$115.25M
EBITDA
-$109.81M
Free cash flow
-$114.96M
Per share
EPS
-$3.56
Free cash flow per share
-$3.44
Book value per share
$10.07
Revenue per share
$0
TBVPS
$10.51
Balance sheet
Total assets
$350.66M
Total liabilities
$28.21M
Debt
$12.64M
Equity
$322.46M
Working capital
$271.1M
Liquidity
Debt to equity
0.04
Current ratio
15.22
Quick ratio
14.76
Net debt/EBITDA
2.13
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.1%
Return on equity
-36.9%
Return on invested capital
-80.7%
Return on capital employed
-34.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IGMS stock price

How has the IGM Biosciences stock price performed over time
Intraday
3.16%
1 week
-2.99%
1 month
-1.86%
1 year
2.69%
YTD
-20.13%
QTD
-15.24%

Financial performance

How have IGM Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$115.74M
Net income
-$115.25M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 88% YoY and by 21% QoQ
The operating income has dropped by 79% year-on-year and by 20% since the previous quarter

Growth

What is IGM Biosciences's growth rate over time

Valuation

What is IGM Biosciences stock price valuation
P/E
N/A
P/B
7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 146% year-on-year and by 18% since the previous quarter
IGM Biosciences's equity has soared by 56% YoY but it has decreased by 9% from the previous quarter
The stock's P/B is 19% below its last 4 quarters average of 8.6

Efficiency

How efficient is IGM Biosciences business performance
The return on invested capital has dropped by 134% year-on-year and by 42% since the previous quarter
The ROA has contracted by 39% YoY and by 10% from the previous quarter
IGMS's return on equity is down by 39% year-on-year and by 9% since the previous quarter

Dividends

What is IGMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IGMS.

Financial health

How did IGM Biosciences financials performed over time
The total assets has soared by 53% year-on-year but it has declined by 8% since the previous quarter
IGM Biosciences's current ratio has decreased by 34% QoQ and by 15% YoY
IGM Biosciences's debt is 96% less than its equity
IGM Biosciences's equity has soared by 56% YoY but it has decreased by 9% from the previous quarter
IGMS's debt to equity is down by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.